Jan van de Winkel, Genmab CEO

Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Just over a month af­ter land­ing their first ap­proval for ep­cori­ta­m­ab, now brand­ed as Ep­kin­ly, Gen­mab and Ab­b­Vie have a fresh slate of da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.